FDA Approved: GA-68-DOTATOC — Original Application (UIHC P E T Imaging Center)

View source ↗

Summary

FDA approved GA-68-DOTATOC (edotreotide gallium-68) in an Original Application for PET imaging of somatostatin receptor-positive neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Ga-68-DOTATOC (Gallium-68 DOTATOC)

Snippet

ORIG AP for GA-68-DOTATOC (EDOTREOTIDE GALLIUM GA-68)